NASDAQ$GRCE
Grace Therapeutics Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Grace Therapeutics reported results for the third fiscal quarter of 2025, announcing positive topline data from the Phase 3 STRIVE-ON safety trial and securing up to $30 million in gross proceeds from a private placement financing.
Grace Therapeutics reported a net loss of $4.2 million, or $0.36 per share, for the quarter ended December 31, 2024. The company announced positive topline data from its Phase 3 STRIVE-ON safety trial and secured up to $30 million in gross proceeds from a private placement financing.
- Phase 3 STRIVE-ON safety trial met primary endpoint, demonstrating clinical benefit compared to orally administered nimodipine.
- NDA submission to the FDA is anticipated in the first half of calendar year 2025 for GTx-104.
- Secured private placement financing of up to approximately $30.0 million in potential total gross proceeds.
- Received written responses to its End of Phase 1 meeting in GTx-102 where the FDA made recommendations on the path toward an NDA.
Headline financials
Revenue & EPS history
Acasti Pharma · Revenue · Quarterly
$0
Forward guidance
Grace Therapeutics focuses on finalizing NDA submission for GTx-104 by the end of June 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q3 2025
+0.7%
Avg return
Earnings day
+31.8%
Avg return
5 days after
+22.6%
Avg return
30 days after
44%
7 / 16 earnings
Positive
+12.3%
Q3 2022
Best reaction
-5.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +2.3% | +4.3% | +9.2% | |
| Q1 2026 | +3.5% | +5.2% | +3.9% | |
| Q4 2025 | -2.3% | -1.0% | +11.7% | |
| Q4 2024 | +1.6% | -3.6% | +9.4% | |
| Q3 2025 | +0.0% | -1.7% | -37.4% | |
| Q1 2025 | -1.0% | -11.7% | -16.5% | |
| Q2 2025 | +3.8% | -0.9% | +12.2% | |
| Q3 2024 | -1.2% | +34.7% | +38.8% | |
| Q2 2024 | -2.0% | -2.3% | -4.5% | |
| Q1 2024 | -1.9% | +17.0% | -22.0% | |
| Q4 2023 | -5.3% | -7.0% | -25.7% | |
| Q3 2022 | +12.3% | -1.6% | -28.1% | |
| Q2 2022 | -3.6% | -14.0% | -30.0% | |
| Q4 2022 | -3.2% | +491.2% | +471.7% | |
| Q3 2021 | +7.0% | +3.5% | -10.5% | |
| Q1 2022 | +1.7% | -3.4% | -20.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro